Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 4
2004 10
2005 11
2006 5
2007 11
2008 9
2009 10
2010 6
2011 8
2012 14
2013 21
2014 35
2015 46
2016 52
2017 34
2018 36
2019 68
2020 59
2021 49
2022 45
2023 36
2024 27
2025 27
2026 8

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

549 results

Results by year

Filters applied: . Clear all
Page 1
Real-world effectiveness of CDK4/6 inhibitors in older patients with HR+/HER2- advanced breast cancer: a sub-analysis of the multicenter, PALMARES-2 study.
Ligorio F, Provenzano L, Fotia G, Dieci MV, Curigliano G, Giuliano M, Botticelli A, Lambertini M, Rizzo G, Pedersini R, Sirico M, La Verde N, Gennari A, Zambelli A, Toss A, Piras M, Giordano M, Tagliaferri B, Generali D, Sartori D, Mazzoli G, Jacobs F, Armani G, Sposetti C, Zurlo C, Menichetti A, Griguolo G, Faso V, Boldrini L, Munzone E, Marra A, Chiappe E, Scagnoli S, Pisegna S, Capasso C, De Angelis C, Arpino G, Criscitiello C, Guarneri V, Pruneri G, Mariani L; PALMARES-2 study group; Vernieri C. Ligorio F, et al. Breast. 2026 Mar 31;87:104769. doi: 10.1016/j.breast.2026.104769. Online ahead of print. Breast. 2026. PMID: 42048902 Free PMC article.
Network analysis predicts pembrolizumab response in advanced NSCLC with PD-L1 < 50.
Occhipinti M, Cruoglio A, Marchesi S, Prelaj A, Petrilli M, Rughetti A, Ambrosini P, Ferretti E, Proto C, Ganzinelli M, Brambilla M, Mazzeo L, Beninato T, de Braud F, Garassino MC, Farina L, Lo Russo G, Petti M. Occhipinti M, et al. Among authors: de braud f. Cancer Cell Int. 2026 Mar 26;26(1):190. doi: 10.1186/s12935-026-04268-5. Cancer Cell Int. 2026. PMID: 41888909 Free PMC article.
APOLLO11: a bio-data-driven model for clinical and translational research in lung cancer.
Prelaj A, Provenzano L, Miskovic V, Ganzinelli M, Mazzeo L, Gemelli M, Silvestri C, Spagnoletti A, Romanò R, Brambilla M, Occhipinti M, Beninato T, Ambrosini P, Sottotetti E, Favali M, Zec A, Ferrarin A, Corrao G, Prina MM, Ruggirello M, Marino MB, Dumitrascu AD, Di Mauro RM, Giani C, Cavalli C, Serino R, Catania C, Panzardi A, Metro G, Bennati C, Ferrara R, Macerelli M, Servetto A, Cona MS, La Verde N, Toschi L, Baili P, Corso F, Zito E, Cinieri S, Berardi R, Scoazec G, Inno A, Gori S, Pisconti S, Buzzacchino F, Brighenti M, Biello F, Tartarone A, Pruneri G, Belfiore A, Agnelli L, Guidi A, Invernizzi L, Salmistraro N, Filippi AR, Solli P, Galli G, Lorenzini D, Pizzutilo EG, De Braud F, Pedrocchi A, Trovò F, Genova C, Corte CMD, Viscardi G, Garassino MC, Cortellini A, Mingo E, Russano M, Signorelli D, Proto C, Vingiani A, Sangaletti S, Lo Russo G; APOLLO11 study group. Prelaj A, et al. Among authors: de braud f. NPJ Precis Oncol. 2026 Jan 29;10(1):96. doi: 10.1038/s41698-026-01295-3. NPJ Precis Oncol. 2026. PMID: 41611893 Free PMC article.
FOLFOX Versus FOLFIRI as Second-Line Chemotherapy in Patients With Advanced Biliary Tract Cancers: A Multicenter, Italian Study.
Pircher C, Nichetti F, Rizzato MD, Bensi M, Salani F, Balsano R, Rota S, Sciortino C, Paolo GD, Trovato G, Genovesi V, Bozzarelli S, Busset MDD, Marchesi S, Gusmaroli E, Mazzaferro V, Salvatore L, Vivaldi C, Sperotto S, Rimassa L, de Braud F, Pietrantonio F, Lonardi S, Niger M. Pircher C, et al. Among authors: de braud f. Liver Int. 2026 Feb;46(2):e70502. doi: 10.1111/liv.70502. Liver Int. 2026. PMID: 41467999
Benchmarking progression-free survival ratio as primary endpoint in precision oncology clinical trials.
Nichetti F, Hüllein J, du Rusquec P, Pleasance E, Chen L, Mock A, Horak P, Ambrosini P, Rota S, Niger M, Agnelli L, Tinè G, Edelmann D, Le Tourneau C, Laskin J, Pruneri G, Wang C, Hübschmann D, de Braud F, Fröhling S, Mariani L. Nichetti F, et al. Among authors: de braud f. NPJ Precis Oncol. 2025 Dec 15;10(1):38. doi: 10.1038/s41698-025-01231-x. NPJ Precis Oncol. 2025. PMID: 41398053 Free PMC article.
UpSMART: five years of digital innovation in cancer clinical research-achievements, challenges, and recommendations.
O'Regan P, Butt F, Carter L, Graham DM, Le Blanc A, Hoskins R, Stephenson L, Patil A, Shabbir M, Eken D, Singh S, Villa A, Agnelli L, Damian S, Grave C, Pretelli G, Garralda E, Frost H, de Braud F, Freitas A, Dive C, Unsworth H. O'Regan P, et al. Among authors: de braud f. Front Digit Health. 2025 Nov 27;7:1708067. doi: 10.3389/fdgth.2025.1708067. eCollection 2025. Front Digit Health. 2025. PMID: 41395630 Free PMC article.
Fasting boosts breast cancer therapy efficacy via glucocorticoid activation.
Padrão N, Severson TM, Gregoricchio S, Guijarro A, Lutz C, Taranto D, Hutten S, Ligorio F, Persia A, Roest M, Sanders J, Song JY, Pires-Oliveira S, Donaldson Collier M, Horlings H, Pisciotta L, de Braud F, Vernieri C, Akkari L, Jonkers J, Nencioni A, Caffa I, Zwart W. Padrão N, et al. Among authors: de braud f. Nature. 2026 Jan;649(8098):1013-1021. doi: 10.1038/s41586-025-09869-0. Epub 2025 Dec 10. Nature. 2026. PMID: 41372410 Free PMC article. Clinical Trial.
Combining Clinician Expertise with Prompt Engineering enhances Small Language Models Reliability for Cancer Entity Recognition in Electronic Health Records.
Corso F, Peppoloni V, Mazzeo L, Leone G, Passos L, Mišković V, Armanini J, Ferrarin A, Wiest IC, Wolf F, Montelatici G, Romanò R, Paolo A, Capoccia T, Natangelo S, Rota S, Andena P, De Ponti M, Russo A, Stasi G, Provenzano L, Spagnoletti A, Meazza Prina M, Cavalli C, Giani C, Serino R, Borracino M, Bonalume C, di Mauro RM, Agosta C, Dumitrascu AD, Di Liberti G, Corrao G, Beninato T, Ganzinelli M, Occhipinti M, Brambilla M, Proto C, Kather JN, Pedrocchi ALG, De Braud F, Lo Russo G, Baili P, Prelaj A. Corso F, et al. Among authors: de braud f. medRxiv [Preprint]. 2025 Oct 21:2025.10.16.25337917. doi: 10.1101/2025.10.16.25337917. medRxiv. 2025. PMID: 41282683 Free PMC article. Preprint.
Zanidatamab in HER2-Positive Metastatic Biliary Tract Cancer: Final Results From HERIZON-BTC-01.
Pant S, Fan J, Oh DY, Choi HJ, Kim JW, Chang HM, Bao L, Sun HC, Macarulla T, Xie F, Metges JP, Ying J, Bridgewater J, Lee MA, Tejani MA, Chen EY, Wasan H, Ducreux M, Bao Y, Wu X, Zhao Y, Garfin PM, Gable J, Harding JJ; HERIZON-BTC-01 Study Group. Pant S, et al. JAMA Oncol. 2026 Jan 1;12(1):106-109. doi: 10.1001/jamaoncol.2025.4736. JAMA Oncol. 2026. PMID: 41264278 Free PMC article.
549 results